127 related articles for article (PubMed ID: 37100735)
1. Effect of Mammalian Target of Rapamycin Inhibition on Activated Regulatory T-Cell Expansion in Kidney Transplantation.
Tomita Y; Uehara S; Takiguchi S; Nakamura M
Transplant Proc; 2023 May; 55(4):792-796. PubMed ID: 37100735
[TBL] [Abstract][Full Text] [Related]
2. Treatment with mTOR inhibitors after liver transplantation enables a sustained increase in regulatory T-cells while preserving their suppressive capacity.
Ghazal K; Stenard F; Dahlqvist G; Barjon C; Aoudjehane L; Scatton O; Conti F
Clin Res Hepatol Gastroenterol; 2018 Jun; 42(3):237-244. PubMed ID: 29175009
[TBL] [Abstract][Full Text] [Related]
3. mTOR Inhibitor Everolimus in Regulatory T Cell Expansion for Clinical Application in Transplantation.
Gedaly R; De Stefano F; Turcios L; Hill M; Hidalgo G; Mitov MI; Alstott MC; Butterfield DA; Mitchell HC; Hart J; Al-Attar A; Jennings CD; Marti F
Transplantation; 2019 Apr; 103(4):705-715. PubMed ID: 30451741
[TBL] [Abstract][Full Text] [Related]
4. Suppression of Allograft Fibrosis by Regulation of Mammalian Target of Rapamycin-Related Protein Expression in Kidney-Transplanted Recipients Treated with Everolimus and Reduced Tacrolimus.
Nishioka S; Ishimura T; Endo T; Yokoyama N; Ogawa S; Fujisawa M
Ann Transplant; 2021 Jan; 26():e926476. PubMed ID: 33431785
[TBL] [Abstract][Full Text] [Related]
5. An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients.
Sommerer C; Suwelack B; Dragun D; Schenker P; Hauser IA; Witzke O; Hugo C; Kamar N; Merville P; Junge M; Thaiss F; Nashan B;
Kidney Int; 2019 Jul; 96(1):231-244. PubMed ID: 31027892
[TBL] [Abstract][Full Text] [Related]
6. Mechanistic analyses in kidney transplant recipients prospectively randomized to two steroid free regimen-Low dose Tacrolimus with Everolimus versus standard dose Tacrolimus with Mycophenolate Mofetil.
Traitanon O; Mathew JM; Shetty A; Bontha SV; Maluf DG; El Kassis Y; Park SH; Han J; Ansari MJ; Leventhal JR; Mas V; Gallon L
PLoS One; 2019; 14(5):e0216300. PubMed ID: 31136582
[TBL] [Abstract][Full Text] [Related]
7. Association of Clinical Events With Everolimus Exposure in Kidney Transplant Patients Receiving Low Doses of Tacrolimus.
Shihab F; Qazi Y; Mulgaonkar S; McCague K; Patel D; Peddi VR; Shaffer D
Am J Transplant; 2017 Sep; 17(9):2363-2371. PubMed ID: 28141897
[TBL] [Abstract][Full Text] [Related]
8. The effect of anti-thymocyte globulin and everolimus on the kinetics of cytomegalovirus viral load in seropositive kidney transplant recipients without prophylaxis.
Basso G; Felipe CR; Cristelli MP; Mansur Siliano J; Viana L; Ferreira Brigido AN; Stopa Martins SB; de Castro Lima Santos DW; Aguiar WF; Tedesco-Silva Junior H; Medina-Pestana JO
Transpl Infect Dis; 2018 Aug; 20(4):e12919. PubMed ID: 29797676
[TBL] [Abstract][Full Text] [Related]
9. Sirolimus vs mycophenolate moftile in Tacrolimus based therapy following induction with Antithymocyte globulin promotes regulatory T cell expansion and inhibits RORγt and T-bet expression in kidney transplantation.
Jamali S; Sarafnejad A; Ahmadpoor P; Nafar M; Karimi M; Eteghadi A; Yekaninejad MS; Amirzargar AA
Hum Immunol; 2019 Sep; 80(9):739-747. PubMed ID: 30597187
[TBL] [Abstract][Full Text] [Related]
10. Focus on mTOR inhibitors and tacrolimus in renal transplantation: pharmacokinetics, exposure-response relationships, and clinical outcomes.
Shihab F; Christians U; Smith L; Wellen JR; Kaplan B
Transpl Immunol; 2014 Jun; 31(1):22-32. PubMed ID: 24861504
[TBL] [Abstract][Full Text] [Related]
11. mTOR Inhibitor Therapy Diminishes Circulating CD8+ CD28- Effector Memory T Cells and Improves Allograft Inflammation in Belatacept-refractory Renal Allograft Rejection.
Castro-Rojas CM; Godarova A; Shi T; Hummel SA; Shields A; Tremblay S; Alloway RR; Jordan MB; Woodle ES; Hildeman DA
Transplantation; 2020 May; 104(5):1058-1069. PubMed ID: 31415033
[TBL] [Abstract][Full Text] [Related]
12. Three-year outcomes from the CRADLE study in de novo pediatric kidney transplant recipients receiving everolimus with reduced tacrolimus and early steroid withdrawal.
Tönshoff B; Tedesco-Silva H; Ettenger R; Christian M; Bjerre A; Dello Strologo L; Marks SD; Pape L; Veldandi U; Lopez P; Cousin M; Pandey P; Meier M
Am J Transplant; 2021 Jan; 21(1):123-137. PubMed ID: 32406111
[TBL] [Abstract][Full Text] [Related]
13. CD45RA
Tomita Y; Ishida H; Uehara S; Takiguchi S; Sato T; Nakamura M
Int Immunopharmacol; 2021 Aug; 97():107661. PubMed ID: 33887579
[TBL] [Abstract][Full Text] [Related]
14. Donor-Specific Anti-Human Leukocyte Antigens Antibodies, Acute Rejection, Renal Function, and Histology in Kidney Transplant Recipients Receiving Tacrolimus and Everolimus.
Ferreira A; Felipe C; Cristelli M; Viana L; Basso G; Stopa S; Mansur J; Ivani M; Bessa A; Ruppel P; Aguiar W; Campos E; Gerbase-DeLima M; Proença H; Tedesco-Silva H; Medina-Pestana J
Am J Nephrol; 2017; 45(6):497-508. PubMed ID: 28511172
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Everolimus Plus Low-Dose Tacrolimus Versus Mycophenolate Mofetil Plus Standard-Dose Tacrolimus in De Novo Renal Transplant Recipients: 12-Month Data.
Qazi Y; Shaffer D; Kaplan B; Kim DY; Luan FL; Peddi VR; Shihab F; Tomlanovich S; Yilmaz S; McCague K; Patel D; Mulgaonkar S
Am J Transplant; 2017 May; 17(5):1358-1369. PubMed ID: 27775865
[TBL] [Abstract][Full Text] [Related]
16. The effect of mammalian target of rapamycin inhibition on T helper type 17 and regulatory T cell differentiation in vitro and in vivo in kidney transplant recipients.
Kim KW; Chung BH; Kim BM; Cho ML; Yang CW
Immunology; 2015 Jan; 144(1):68-78. PubMed ID: 24974886
[TBL] [Abstract][Full Text] [Related]
17. Impact of Everolimus-based Immunosuppression on Renal Function in Liver Transplant Recipients.
Nogueras López F; Abellan Alfocea P; Ortega Suazo EJ; López Garrido MA; Becerra Massare A; Gila Medina AM; Redondo Cerezo E; Espinosa Aguilar MD
Transplant Proc; 2020 Mar; 52(2):556-558. PubMed ID: 32035673
[TBL] [Abstract][Full Text] [Related]
18. Pharmacodynamic monitoring of mammalian target of rapamycin inhibition by phosphoflow cytometric determination of p70S6 kinase activity.
Hoerning A; Wilde B; Wang J; Tebbe B; Jing L; Wang X; Jian F; Zhu J; Dolff S; Kribben A; Hoyer PF; Witzke O
Transplantation; 2015 Jan; 99(1):210-9. PubMed ID: 25099702
[TBL] [Abstract][Full Text] [Related]
19. Oscillatory mTOR inhibition and Treg increase in kidney transplantation.
Sabbatini M; Ruggiero G; Palatucci AT; Rubino V; Federico S; Giovazzino A; Apicella L; Santopaolo M; Matarese G; Galgani M; Terrazzano G
Clin Exp Immunol; 2015 Nov; 182(2):230-40. PubMed ID: 26077103
[TBL] [Abstract][Full Text] [Related]
20. The influence of mTOR inhibitors on the incidence of CMV infection in high-risk donor positive-recipient negative (D+/R-) kidney transplant recipients.
Cristelli MP; Esmeraldo RM; Pinto CM; Sandes-Freitas TV; Felipe C; Lobo CF; Viana L; Mansur J; Stopa S; Santos DWC; Grenzi PC; Aguiar WF; Tedesco-Silva H; Pestana JOM
Transpl Infect Dis; 2018 Aug; 20(4):e12907. PubMed ID: 29679515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
